Phys Vivas · endocrine
Adrenal Incidentaloma AND Workup — Viva Defence
DCE viva defence for Adrenal Incidentaloma AND Workup.
On this page & tools
Target exams
Adrenal Incidentaloma AND Workup Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Adrenal Incidentaloma AND Workup. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
Short case
Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]
References
- [1]Mogl MT [Diagnostics and surgery of mild autonomous cortisol secretion (MACS)] Chirurgie (Heidelb), 2026.PMID 41642322
- [2]Pal B, Halder A, Mallik D, Kannaujiya V, et al. Plan of Management of Adrenal Incidentaloma Diagnosed with Carcinoma Colon: A Case Report and Review of Literature Case Rep Oncol, 2026.PMID 41552648
- [3]Nazario-Perez MZ, Ceballos-Alvarez KE, Gonzalez-Figueroa G, Pastrana-Echevarria I, et al. Primary cholangiocarcinoma of the adrenal gland: a surgical and diagnostic challenge - a case report BMC Urol, 2025.PMID 41275156
- [4]Kmieć P, Okroj D, Zdrojewska M, Fiszer J, et al. Overnight Dexamethasone in Primary Aldosteronism Screening in Patients on Interfering Therapy (ODEPRASC): A Diagnostic Interpretability Study Protocol J Clin Hypertens (Greenwich), 2025.PMID 41268804
- [5]O'Connor JP, Poloju A, Pabich SK, Allen B, et al. Unveiling the Silent Threat: Disparities in Adrenal Incidentaloma Management J Surg Res, 2025.PMID 40424844
- [6]Savoie PH, Murez T, Rocher L, Neuville P, et al. French AFU Cancer Committee Guidelines - Update 2024-2026 : Assessment of an adrenal incidentaloma and oncological management Fr J Urol, 2024.PMID 39581666
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922